Aclaris Therapeutics, Inc. (ACRS)
NASDAQ: ACRS · Real-Time Price · USD
3.750
-0.050 (-1.32%)
At close: Apr 7, 2026, 4:00 PM EDT
4.000
+0.250 (6.67%)
Pre-market: Apr 8, 2026, 5:18 AM EDT
Aclaris Therapeutics Revenue
In the year 2025, Aclaris Therapeutics had annual revenue of $7.83M, down -58.19%. Aclaris Therapeutics had revenue of $1.30M in the quarter ending December 31, 2025, a decrease of -85.94%.
Revenue (ttm)
$7.83M
Revenue Growth
-58.20%
P/S Ratio
66.60
Revenue / Employee
$107,205
Employees
73
Market Cap
521.23M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.83M | -10.89M | -58.19% |
| Dec 31, 2024 | 18.72M | -12.53M | -40.09% |
| Dec 31, 2023 | 31.25M | 1.50M | 5.03% |
| Dec 31, 2022 | 29.75M | 22.99M | 340.05% |
| Dec 31, 2021 | 6.76M | 279.00K | 4.30% |
| Dec 31, 2020 | 6.48M | 2.26M | 53.35% |
| Dec 31, 2019 | 4.23M | -1.92M | -31.28% |
| Dec 31, 2018 | 6.15M | 4.47M | 265.48% |
| Dec 31, 2017 | 1.68M | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| MiMedx Group | 418.63M |
| CorMedix | 311.71M |
| Valneva SE | 205.07M |
| Zevra Therapeutics | 106.47M |
| Fulcrum Therapeutics | 80.00M |
| Prothena Corporation | 9.68M |
| Upstream Bio | 2.85M |
| ProKidney | 893.00K |
ACRS News
- 11 days ago - Results Presented at 2026 American Academy of Dermatology (AAD) Annual Meeting Provide Additional Support for the Therapeutic Potential of ATI-2138 - GlobeNewsWire
- 18 days ago - Aclaris Therapeutics Announces Poster on Results from Phase 2a Trial of ATI-2138 at the 2026 American Academy of Dermatology (AAD) Annual Meeting - GlobeNewsWire
- 20 days ago - Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis - GlobeNewsWire
- 5 weeks ago - Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 6 weeks ago - Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Patients with Asthma with its Novel Bispecific Anti-TSLP/IL-4Rα Antibody ATI-052 - GlobeNewsWire
- 2 months ago - Aclaris Therapeutics' Novel ITK/JAK3 Inhibitor ATI-2138 Demonstrates Rapid and Sustained Hair Regrowth in Validated Murine Model of Alopecia Areata (AA) - GlobeNewsWire
- 3 months ago - Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Atopic Dermatitis (AD) with Its Novel Bispecific Antibody ATI-052 - GlobeNewsWire
- 3 months ago - Aclaris Therapeutics Announces Positive Interim Results of Phase 1a Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 Supporting Expedited Clinical Development - GlobeNewsWire